Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat M...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

Sw1ngb0t Aug. 21 at 6:04 AM

$PRLD finally got back to the top

0 · Reply

Jaybird827 Aug. 20 at 11:13 PM

$PRLD it did these last November and didn’t hold bu I’m not selling. Been here since 2022 5,500 shares strong. Good luck

1 · Reply

exp8triot Aug. 20 at 10:32 PM

$PRLD I'm smelling a massive day tommororow

0 · Reply

vu_jade Aug. 20 at 9:30 PM

$PRLD Beast mode!

0 · Reply

topstockalerts Aug. 20 at 9:25 PM

$PRLD the chart is developing in a very healthy way.

0 · Reply

Jaybird827 Aug. 20 at 9:22 PM

$PRLD what is going on after hours

1 · Reply

elitechrisvp Aug. 20 at 5:31 PM

$PRLD love these names before there's any followers. 😎 $IBRX $SLS

0 · Reply

LabPsycho Aug. 20 at 5:02 PM

$PRLD @tradingjunk321 @elitechrisvp Nice work. When I get some time I am going to post my faux Investment Thesis why I think this is going substantially higher.

1 · Reply

trad0r83 Aug. 20 at 5:00 PM

$SLS rocket incoming from $PRLD

0 · Reply

kp8claw Aug. 20 at 3:54 PM

0 · Reply

Prelude Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 13 days ago

Prelude Therapeutics Quarterly report: Q2 2026

2026-08-11T11:20:47.000Z - 13 days ago

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

Aug 10, 2026, 7:00 AM EDT - 14 days ago

Prelude Therapeutics Slides: Corporate presentation

2026-07-28T14:45:41.000Z - 27 days ago

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

INCY

Jun 10, 2026, 11:20 AM EDT - 2 months ago

Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 8:30 AM EDT - 2 months ago

Prelude Therapeutics Transcript: AGM 2026

Jun 3, 2026, 12:15 PM EDT - 2 months ago

Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-05-15T09:13:07.000Z - 3 months ago

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

2026-05-12T11:55:16.000Z - 3 months ago

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

May 12, 2026, 7:01 AM EDT - 3 months ago

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Slides: Corporate presentation

2026-05-04T11:35:31.000Z - 4 months ago

Prelude Therapeutics initiated with a Buy at D. Boral Capital

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Prelude Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Prelude Therapeutics Proxy statement: Proxy filing

2026-04-27T11:53:08.000Z - 4 months ago

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Prelude Therapeutics Slides: Corporate presentation

2026-04-20T10:34:29.000Z - 4 months ago

Prelude Therapeutics presents new preclinical data from PRT13722 study

Apr 20, 2026, 6:30 AM EDT - 4 months ago

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Apr 20, 2026, 6:00 AM EDT - 4 months ago

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:51:11.000Z - 4 months ago

Prelude Therapeutics announces Charles Morris as chief medical officer

Apr 15, 2026, 7:30 AM EDT - 4 months ago

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

2026-03-18T18:55:15.000Z - 5 months ago

Prelude Therapeutics management to meet with Citizens

Mar 17, 2026, 4:31 PM EDT - 5 months ago

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

2026-03-11T09:15:25.000Z - 5 months ago

Prelude Therapeutics price target raised to $6 from $3 at Citizens

Mar 10, 2026, 3:25 PM EDT - 5 months ago

Prelude Therapeutics Transcript: Conference

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Prelude Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Prelude Therapeutics Earnings release: Q4 2025

2026-03-10T11:10:26.000Z - 5 months ago

Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

2026-03-10T11:10:14.000Z - 5 months ago

Prelude Therapeutics sees cash runway into 2Q27

Mar 10, 2026, 7:01 AM EDT - 5 months ago

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Prelude Therapeutics Slides: Corporate presentation

2026-02-03T14:10:10.000Z - 7 months ago

Prelude receives FDA clearance for investigational IND for PRT12396

Feb 3, 2026, 9:00 AM EST - 7 months ago

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

2025-12-10T21:16:07.000Z - 9 months ago

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

Dec 10, 2025, 7:00 AM EST - 9 months ago

Prelude Therapeutics Registration statement: Registration Filing

2025-12-07T18:15:23.000Z - 9 months ago

Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs

Dec 6, 2025, 11:00 AM EST - 9 months ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Nov 12, 2025, 8:00 AM EST - 10 months ago

Prelude Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Prelude Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Prelude Therapeutics Earnings release: Q3 2025

2025-11-12T12:22:24.000Z - 10 months ago

Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year

2025-11-12T12:22:00.000Z - 10 months ago

Prelude Therapeutics sees cash runway into 2027

Nov 12, 2025, 7:01 AM EST - 10 months ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 7:05 AM EST - 10 months ago

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:01 AM EST - 10 months ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 3, 2025, 9:01 AM EST - 10 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Nov 3, 2025, 7:00 AM EST - 10 months ago

Prelude Therapeutics Slides: Corporate Presentation

Oct 17, 2025, 7:30 AM EDT - 11 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q2 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Prelude Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 7, 2025, 11:00 AM EDT - 1 year ago

Prelude Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 4:05 PM EDT - 1 year ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 12:30 PM EDT - 1 year ago

Prelude Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Annual report: Q4 2024

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Dec 2, 2024, 11:30 AM EST - 1 year ago

Prelude Therapeutics Transcript: The Citizens JMP Hematology and Oncology Summit Conference

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Earnings release: Q3 2024

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 2 years ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 2 years ago

Prelude Therapeutics Slides: Study Update

Sep 13, 2024, 10:00 AM EDT - 2 years ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 2 years ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q2 2024

Jul 9, 2024, 7:30 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Jun 12, 2024, 10:40 AM EDT - 2 years ago

Prelude Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 1:30 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

May 14, 2024, 1:00 PM EDT - 2 years ago

Prelude Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 4:35 PM EDT - 2 years ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 13, 2024, 3:05 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 16, 2024, 7:00 AM EST - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Annual report: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Earnings release: Q4 2023

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 3 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Nov 1, 2023, 4:00 PM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 4:00 PM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q3 2023

Oct 14, 2023, 12:30 PM EDT - 3 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Sep 12, 2023, 4:55 PM EDT - 3 years ago

Prelude Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 4:30 PM EDT - 3 years ago

Prelude Therapeutics Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 29, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q2 2023

May 31, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 3 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q1 2023

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 27, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Annual report: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q4 2022

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Sw1ngb0t Aug. 21 at 6:04 AM

$PRLD finally got back to the top

0 · Reply

Jaybird827 Aug. 20 at 11:13 PM

$PRLD it did these last November and didn’t hold bu I’m not selling. Been here since 2022 5,500 shares strong. Good luck

1 · Reply

exp8triot Aug. 20 at 10:32 PM

$PRLD I'm smelling a massive day tommororow

0 · Reply

vu_jade Aug. 20 at 9:30 PM

$PRLD Beast mode!

0 · Reply

topstockalerts Aug. 20 at 9:25 PM

$PRLD the chart is developing in a very healthy way.

0 · Reply

Jaybird827 Aug. 20 at 9:22 PM

$PRLD what is going on after hours

1 · Reply

elitechrisvp Aug. 20 at 5:31 PM

$PRLD love these names before there's any followers. 😎 $IBRX $SLS

0 · Reply

LabPsycho Aug. 20 at 5:02 PM

$PRLD @tradingjunk321 @elitechrisvp Nice work. When I get some time I am going to post my faux Investment Thesis why I think this is going substantially higher.

1 · Reply

trad0r83 Aug. 20 at 5:00 PM

$SLS rocket incoming from $PRLD

0 · Reply

kp8claw Aug. 20 at 3:54 PM

0 · Reply

outlawinvestor1 Aug. 20 at 3:43 PM

$PRLD i never thought this company would rise this much!?! congrats to all long term shareholders. 🥳

0 · Reply

elitechrisvp Aug. 20 at 3:24 PM

$PRLD another big winner, hope I'm not letting go too soon!! (got plans for the cash) $IBRX

4 · Reply

exp8triot Aug. 18 at 5:55 PM

$PRLD lots of options being purchased....

1 · Reply

tiddyy Aug. 12 at 8:44 PM

$PRLD I should have bought 😭

1 · Reply

elitechrisvp Aug. 11 at 6:56 PM

$PRLD nice job, let's see the same ride over here $IBRX

0 · Reply

elitechrisvp Aug. 11 at 6:39 PM

$PRLD good day ✅️

0 · Reply

focafoca99 Aug. 11 at 12:27 PM

$PRLD discussed its Q2 2026 financial results.

1 · Reply

tiddyy Aug. 4 at 12:48 PM

$PRLD I am so tempted to buy this, but this is so high already. Only thing is OrbiMed purchased some shares, and Baker Bros got a lot of options purchased around the $4 price This looks really interesting, also the Incyte deal. I want to get in so bad but I would prefer to get in the $3

1 · Reply

LSOTradingDesk Jul. 31 at 10:54 AM

$PGEN and $PRLD 🤔

0 · Reply

LabPsycho Jul. 30 at 8:22 PM

$PRLD I get the feeling this place is just outsourcing all their R&D. I can not seem to find any of their structures. Why do they bother publishing something like this where their molecule is represented as a circle - thats not a good look of competence IMO.

1 · Reply

elitechrisvp Jul. 30 at 7:37 PM

$PRLD looking good! ✅️👍

0 · Reply

KUMO2026 Jul. 30 at 1:58 PM

$PRLD 5.06 swing exit

1 · Reply

Market Cap	528.05M
Revenue (ttm)	12.14M
Net Income (ttm)	-99.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-819.60%
Debt to Equity Ratio	0.00

Volume	519,200
Avg Vol	504,204
Day's Range	N/A - N/A
Shares Out	79.65M
Stochastic %K	91%
Beta	0.96
Analysts	Strong Sell
Price Target	$8.00